


Status: Currently Official on 15-Feb-2025
 Official Date: Official as of 01-Dec-2020
 Document Type: USP Monographs
 DocId: GUID-AAC6B8E4-86F7-4DC5-A256-89E658ADC7D2_3_en-US
 DOI: https://doi.org/10.31003/USPNF_M35835_03_01
 DOI Ref: ojk31

© 2025 USPC
 Do not distribute

Goserelin Acetate



$C_{59}H_{84}N_{18}O_{14} \cdot xC_2H_4O_2$

1269.43 (as free base)

Luteinizing hormone-releasing factor (pig), 6-[O-(1,1-Dimethylethyl)-D-serine]-10-deglycinamide-, 2-(aminocarbonyl)hydrazide, acetate (salt); 1-(5-Oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-O-tert-butyl-D-seryl-L-leucyl-L-arginyl-L-prolyl)semicarbazide (goserelin free base);

Free base: CAS RN®: 65807-02-5; UNII: 0F65R8P09N.

Acetate salt: CAS RN®: 145781-92-6; UNII: 6YUU2PV0U8.

DEFINITION

Goserelin Acetate is a synthetic nonapeptide analog of the hypothalamic decapeptide, gonadorelin. It is obtained by chemical synthesis and is available as an acetate salt. It contains NLT 94.5% and NMT 103.0% of goserelin ($C_{59}H_{84}N_{18}O_{14}$), calculated on the anhydrous and acetic acid-free basis.

IDENTIFICATION

- **A.** The retention time of the goserelin peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the *Assay*.

ASSAY

• PROCEDURE

Mobile phase: Prepare a filtered and degassed mixture of [water](#), [acetonitrile](#), and [trifluoroacetic acid](#) (1600:400:1).

Standard solution: 1 mg/mL of [USP Goserelin Acetate RS](#) in [water](#)

Diluted standard solution: Transfer 1 mL of the *Standard solution* to a 10-mL volumetric flask, and dilute with [water](#) to volume.

System suitability solution 1: Prepare a solution of 0.1 mg/mL [USP Goserelin Related Compound A RS](#) in [water](#), and mix with an equal volume of *Diluted standard solution*.

System suitability solution 2: Prepare [USP Goserelin System Suitability Mixture RS](#) as indicated on the label.

Sample solution: 1 mg/mL of Goserelin Acetate in [water](#)

Chromatographic system

(See [Chromatography \(621\)](#), [System Suitability](#).)

Mode: LC

Detector: UV 220 nm

Column: 4.6-mm × 15-cm; 3.5-μm packing [L1](#)

Column temperature: 50°–55°

Flow rate: 1 mL/min

Injection volume: 10 μL

System suitability

Samples: *Standard solution, System suitability solution 1, and System suitability solution 2*

[NOTE—For *System suitability solution 1*, the retention time for the goserelin peak is between 40 and 50 min; see [Table 1](#) for the relative retention times. Two minor peaks are visible prior to the elution of the principal peak, *System suitability solution 2*.]

Suitability requirements

Resolution: NLT 7.0 between the goserelin and goserelin related compound A (4-D-Ser-goserelin) peaks, *System suitability solution 1*

Relative standard deviation: NMT 2.0% for the goserelin peak from replicate injections, *Standard solution*

Analysis

Samples: *Standard solution and Sample solution*

Calculate the percentage of goserelin ($C_{59}H_{84}N_{18}O_{14}$) in the portion of Goserelin Acetate taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

r_U = peak response from the *Sample solution*

r_S = peak response from the *Standard solution*

C_S = concentration of the *Standard solution* (mg/mL)

C_U = concentration of the *Sample solution* (mg/mL)

Acceptance criteria: 94.5%–103.0% on the anhydrous, acetic acid-free basis

OTHER COMPONENTS

- [ACETIC ACID IN PEPTIDES \(503\)](#): 4.5%–15.0%

IMPURITIES

Change to read:

- **ORGANIC IMPURITIES: RELATED COMPOUNDS**

Mobile phase, Standard solution, Diluted standard solution, System suitability solution 1, System suitability solution 2, Sample solution, and **Chromatographic system:** Proceed as directed in the Assay.

Diluted sample solution: Transfer 1 mL of the *Sample solution* into a 100-mL volumetric flask, and dilute with [water](#) to volume.

System suitability

Samples: *System suitability solution 1 and System suitability solution 2*

[NOTE—For *System suitability solution 1*, the retention time for the goserelin peak is between 40 and 50 min; see [Table 1](#) for the relative retention times. For *System suitability solution 2*, two peaks, corresponding to decarbamoylgoserelin and 2-D-His-goserelin and eluting prior to the principal peak, are visible.]

Resolution: NLT 7.0, *System suitability solution 1*

Column efficiency: NLT 2000 theoretical plates, *System suitability solution 1*

Tailing factor: NMT 2.0, *System suitability solution 1*

Relative standard deviation: NMT 2.0%, *System suitability solution 2*

Table 1

Name	Relative Retention Time
4-D-Ser-goserelin	0.67
Decarbamoylgoserelin	0.89
5-D-Tyr-goserelin	0.92
2-D-His-goserelin	0.94
▲Goserelin▲ (ERR 1-Dec-2020)	1.0

Analysis

Samples: *Sample solution and Diluted sample solution*

Calculate the percentage of goserelin-related impurities in the portion of Goserelin Acetate taken:

$$\text{Result} = r_i/r_U$$

r_i = peak response for any individual impurity in the *Sample solution*

r_U = peak response of the main goserelin peak in the *Diluted sample solution*

Acceptance criteria

Decarbamoylgoserelin: NMT 1.0%

Any other impurity: NMT 0.5%

Total impurities: NMT 2.5%

SPECIFIC TESTS

• AMINO ACID CONTENT

(See [Nuclear Magnetic Resonance Spectroscopy \(761\)](#).)

[NOTE—Concentrations of goserelin in the *Standard solution* and the *Sample solution* must be the same (within 5% of each other) but can be adjusted based on the quality of the carbon-13 spectra obtained. The spectra must be acquired under the same conditions for both the *Standard solution* and the *Sample solution*. The spectra obtained are of sufficient quality to allow quantification of the integrals of the resonances specified in this test. Integrals and spectra of the *Standard solution* and the *Sample solution* can be repeated and averaged.]

Standard solution: Dissolve [USP Goserelin Acetate RS](#) in [deuterium oxide](#) to obtain a solution having a known concentration of about 10% (w/v), and adjust with deuterated acetic acid-d4 to a pH of 4.

Sample solution: Prepare a 10% (w/v) solution of Goserelin Acetate in [deuterium oxide](#), and adjust with deuterated acetic acid-d4 to a pH of 4.

Analysis

Samples: *Standard solution* and *Sample solution*

Obtain a carbon-13, proton-decoupled nuclear magnetic resonance (NMR) spectrum of both the *Standard solution* and the *Sample solution*. The spectra from the solutions are qualitatively similar, and all the resonances from the spectrum of the *Standard solution* are present in the spectrum of the *Sample solution* and have the same chemical shift values (± 0.1 ppm for goserelin, ± 0.5 ppm for acetate). Identify any other resonances in the spectrum of the *Sample solution*. Integrate the resonances at the approximate parts per million corresponding to each amino acid in [Table 2](#).

Table 2

Amino Acids	Resonances (ppm)
Azo-glycine	162.2
Histidine	118.4
Tyrosine	116.7
tert-Butyl serine	62.2
Serine	62.5
Tryptophan	55.7
Arginine	41.8
Pyroglutamic acid	26.3
Proline	26.0
Leucine	23.5

Calculate the ratio of each of the amino acids from the integrals of the *Standard solution* and the *Sample solution*:

$$\text{Result} = r_U/r_S$$

r_U = integral of the resonance of a designated amino acid from the *Sample solution*

r_s = integral of the resonance of a designated amino acid from the *Standard solution*

Acceptance criteria: 0.9–1.1 for histidine, tyrosine, *tert*-butyl serine, serine, tryptophan, arginine, pyroglutamic acid, proline, and leucine ; 0.8–1.2 for azo-glycine

• **OPTICAL ROTATION (781S), Procedures, Specific Rotation**

Sample solution: 2 mg/mL, in [water](#), calculated on the anhydrous and acetic acid-free basis

Acceptance criteria: Between –52° and –56°

• **BACTERIAL ENDOTOXINS TEST (85):** The level of bacterial endotoxins is such that the requirement under the relevant dosage form monograph(s) in which Goserelin Acetate is used can be met. Where the label states Goserelin Acetate must be subjected to further processing during the preparation of injectable dosage forms, the level of bacterial endotoxins is such that the requirement under the relevant dosage form monograph(s) in which Goserelin Acetate is used can be met.

• **WATER DETERMINATION (921), Method I:** NMT 10.0%

ADDITIONAL REQUIREMENTS

• **PACKAGING AND STORAGE:** Preserve in tight, light-resistant containers, and store in a refrigerator.

• **USP REFERENCE STANDARDS (11).**

[USP Goserelin Acetate RS](#)

[USP Goserelin Related Compound A RS](#)

[USP Goserelin System Suitability Mixture RS](#)

Auxiliary Information - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
GOSERELIN ACETATE	Ying Han Associate Science & Standards Liaison	BI012020 Biologics Monographs 1 - Peptides

Chromatographic Database Information: [Chromatographic Database](#)

Most Recently Appeared In:

Pharmacopeial Forum: Volume No. 45(6)

Current DocID: GUID-AAC6B8E4-86F7-4DC5-A256-89E658ADC7D2_3_en-US

DOI: https://doi.org/10.31003/USPNF_M35835_03_01

DOI ref: [ojk31](#)